These interim consolidated financial statements were subject to a limited review by the Statutory Auditors._____ Results at 30 June 2024 H1 Current Operating Income / Division2023reported basis2024reported basisChange / Reported basisExternal growthChange / Like-for-like basisPharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%Axigate Link4.64.4-0.2-4.9% -0.2-4.9%e-Connect3.62.5-1.1-29.9% -1.1-29.9%Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%Fintech-0.4-0.10.369.3% 0.3-69.3%Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3% PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%) The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Villers-lès-Nancy, 27 September 2024 - 6:00 p.m.(CET) PRESS RELEASE 2024 half-year results Group results impacted by weaker economic conditions and continuing investment efforts in H1: Revenue: €108.0m, -4.1%Current Operating Income: €20.9m, -24.1% Net Profit attributable to the Group: €17.2m, -21.8% Though with a profit margin that continues to be very positive: Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like H1 RESULTS (€M)2023reported basis2024reported basisChange / Reported basisExternal growthChange / Like-for-like basisRevenue 112.6108.0-4.6-4.1%-3.7-8.3-7.4%Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%Net Profit attributable to the Group22.017.2-4.8-21.8% The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024.
Financial calendar: 1 October 2024: Presentation of H1 2024 results7 November 2024: Publication of Q3 2024 revenue6 February 2025: Publication of f Q4/FY 2024 revenue About Group Equasens With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.
The story "Equasens: 2024 half-year results" has 508 words across 17 sentences, which will take approximately 3 - 5 minutes for the average person to read.
Which news outlet covered this story?
The story "Equasens: 2024 half-year results" was covered 11 hours ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 23 news stories per day.
It's most recent story was published 9 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
